Limitless Potential.
Precision Design.
Enduring Impact.
Aiming to transform treatment of cancer and autoimmune and inflammatory diseases by developing allogeneic, iPSC-derived NK and T cell therapies.
PRESS RELEASES + EVENTS
view all
03-June-2024
Century Therapeutics Presents Interim Results from Phase 1 ELiPSE-1 Study at ASCO 2024 Annual Meeting
In ongoing dose escalation, CNTY-101 has demonstrated a manageable safety profile with no observed DLTs…
10-May-2024
Century Therapeutics Presents Preclinical Data Highlighting Advances in iPSC Platform Technology and Programs at 2024 ASGCT Annual Meeting
In vitro data showcases CNTY-101’s ability to induce CD19-specific cytolysis of B-cells and potential to…
About us
We are building an industry leading allogeneic iPSC-derived cell therapy platform for cancer and autoimmune and inflammatory diseases.
OUR SCIENCE
We are leveraging the unlimited self-renewing capacity of induced pluripotent stem cells (iPSC) and cutting-edge cellular engineering and manufacturing technologies to develop fit-for-purpose products with functionalities designed to overcome the limitations of existing cell therapies.
